Rita Pinto-Proença1, Mariana Santos2, Cristina Fonseca3, Júlia Fernandes3, Maria Filomena Gaspar4, Rui Proença3. 1. Ophthalmology Department, Central Lisbon Hospital Center, Hospital de Santo António dos Capuchos, Alameda de Santo António dos Capuchos, 1169-050, Lisbon, Portugal. ritapintoproenca@gmail.com. 2. Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 3. Onco-Ophthalmology National Reference Center, Ophthalmology Department, Hospital and University Center of Coimbra, Coimbra, Portugal. 4. Center for Social Studies, Faculty of Psychology and Education Sciences, University of Coimbra, Coimbra, Portugal.
Abstract
PURPOSE: Conjunctival melanoma is a rare but potentially lethal tumor. Its biologic profile is still largely unknown, with recent studies aiming at establishing histopathological and genetic tumor profiles. The aim of this study was to analyze the association between clinicopathological characteristics and tumor expression of cyclooxygenase-2 (COX-2) to prognosis, assessing its usefulness as a possible prognostic marker. METHODS: Case series of 50 patients from 1991 to 2008 with pathologically proven conjunctival melanoma. Demographic, clinical, and pathological characteristics were evaluated by reviewing clinical files and pathology. Expression of COX-2 was studied by immunohistochemistry of formalin-fixed paraffin-embedded tissue samples of 20 melanomas. Samples were classified in a score which included intensity of staining and percentage of cells with positive reactivity. RESULTS: Clinicopathological features significantly associated (p < .05) with a poor prognosis (death) included involvement of fornix and tarsal conjunctiva, tumor thickness exceeding 2 mm, local tumor recurrence, lymph node, and systemic metastasis. In the immunohistochemistry study (n = 20), 18 cases expressed COX-2 although with different scores. However, only cases with a high score were associated with a poor outcome. Multivariate association analysis revealed that recurrence rate, metastasis, corneal invasion, and tumor thickness were associated with high score cases and, therefore, with a clinical profile with a higher risk of death. CONCLUSIONS: Results suggest that higher COX-2 expression may be a negative prognostic factor in conjunctival melanoma. Further studies can address the potential use of anti-COX-2 drugs as adjuvant therapy of this disease.
PURPOSE:Conjunctival melanoma is a rare but potentially lethal tumor. Its biologic profile is still largely unknown, with recent studies aiming at establishing histopathological and genetic tumor profiles. The aim of this study was to analyze the association between clinicopathological characteristics and tumor expression of cyclooxygenase-2 (COX-2) to prognosis, assessing its usefulness as a possible prognostic marker. METHODS: Case series of 50 patients from 1991 to 2008 with pathologically proven conjunctival melanoma. Demographic, clinical, and pathological characteristics were evaluated by reviewing clinical files and pathology. Expression of COX-2 was studied by immunohistochemistry of formalin-fixed paraffin-embedded tissue samples of 20 melanomas. Samples were classified in a score which included intensity of staining and percentage of cells with positive reactivity. RESULTS: Clinicopathological features significantly associated (p < .05) with a poor prognosis (death) included involvement of fornix and tarsal conjunctiva, tumor thickness exceeding 2 mm, local tumor recurrence, lymph node, and systemic metastasis. In the immunohistochemistry study (n = 20), 18 cases expressed COX-2 although with different scores. However, only cases with a high score were associated with a poor outcome. Multivariate association analysis revealed that recurrence rate, metastasis, corneal invasion, and tumor thickness were associated with high score cases and, therefore, with a clinical profile with a higher risk of death. CONCLUSIONS: Results suggest that higher COX-2 expression may be a negative prognostic factor in conjunctival melanoma. Further studies can address the potential use of anti-COX-2 drugs as adjuvant therapy of this disease.
Authors: Ludwig M Heindl; Carmen Hofmann-Rummelt; Werner Adler; Jacobus J Bosch; Leonard M Holbach; Gottfried O H Naumann; Friedrich E Kruse; Claus Cursiefen Journal: Ophthalmology Date: 2011-08-11 Impact factor: 12.079
Authors: Dimitrios Mougiakakos; C Christian Johansson; Eric Trocme; Charlotta All-Ericsson; Mario A Economou; Olle Larsson; Stefan Seregard; Rolf Kiessling Journal: Cancer Date: 2010-05-01 Impact factor: 6.860
Authors: Jean-Claude A Marshall; Bruno F Fernandes; Sebastian Di Cesare; Shawn C Maloney; Patrick T Logan; Emilia Antecka; Miguel N Burnier Journal: Carcinogenesis Date: 2007-04-13 Impact factor: 4.944